Related Experiment Video
Updated: Jun 1, 2026
09:58
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
Added value with extended NO analysis in atopy and asthma.
Marieann Högman1, Andrei Malinovschi, Dan Norbäck
1Centre for Research and Development, Uppsala University/County Council of Gävleborg, Sweden. marieann.hogman@lg.se
Clinical Physiology and Functional Imaging
|June 16, 2011
Summary
Atopic status is crucial for understanding exhaled nitric oxide (NO) in asthma. Extended NO analysis, focusing on airway diffusion (Daw NO) and airway wall content (Caw NO), shows promise for monitoring rhinitis and asthma treatments.
Area of Science:
- Respiratory Medicine
- Allergology
- Clinical Immunology
Background:
- Exhaled nitric oxide (NO) usefulness in asthma treatment yields conflicting results.
- Atopic status is often not clearly defined in these assessments.
Purpose of the Study:
- To characterize subjects with rhinitis and asthma using extended exhaled NO analysis.
- To investigate the role of atopy in NO parameters within a general population sample.
Main Methods:
- Utilized data from the European Community Respiratory Health Survey II (ECRHS II).
- Included a subgroup (n=284) with multi-flow rate NO measurements.
- Employed a nonlinear model for NO parameters, defining atopy by allergen titres and assessing bronchial responsiveness via methacholine challenge.
Main Results:
- Non-atopic rhinitis and asthma subjects were indistinguishable from healthy individuals based on NO parameters.
- Airway diffusion rate (Daw NO) increased with atopy: healthy (8.0), healthy atopic (8.8), atopic rhinitis (10.6), and atopic asthma (11.2) ml s⁻¹.
- Bronchial responsiveness correlated with Daw NO in atopic rhinitis (r=-0.41) and Caw NO in atopic asthma (r=-0.56).
Conclusions:
- Characterizing atopic status is essential when evaluating NO associations with asthma.
- Extended NO analysis, particularly Daw NO and Caw NO, may aid in monitoring rhinitis and asthma treatment effectiveness.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms: